|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
188,370,000 |
Market
Cap: |
16.70(B) |
Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
52
Week Range: |
$76.22 - $99 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : 811 |
Guru Rank Value : 0.9 |
Guru Occurances : 1 |
|
|
|
|
|
|
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
3,625 |
Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
139,229 |
182,993 |
316,353 |
638,922 |
Total Sell Value |
$12,316,080 |
$16,513,389 |
$28,948,007 |
$60,375,372 |
Total People Sold |
5 |
5 |
6 |
8 |
Total Sell Transactions |
11 |
15 |
24 |
57 |
End Date |
2024-01-25 |
2023-10-24 |
2023-04-25 |
2022-04-25 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-06-04 |
4 |
S |
$62.52 |
$62,521 |
D/D |
(1,000) |
178,257 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
11,400 |
64,426 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-06-03 |
4 |
S |
$59.88 |
$59,876 |
D/D |
(1,000) |
179,257 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-06-03 |
4 |
D |
$60.00 |
$213,720 |
D/D |
(3,562) |
53,026 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-06-02 |
4 |
AS |
$57.83 |
$21,804 |
D/D |
(377) |
20,190 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-05-31 |
4 |
D |
$57.96 |
$17,214 |
D/D |
(297) |
7,993 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-05-31 |
4 |
D |
$57.96 |
$23,937 |
D/D |
(413) |
20,567 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-05-30 |
5 |
GD |
$0.00 |
$0 |
D/D |
180 |
64,246 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-05-30 |
4 |
GD |
$23.21 |
$4,178 |
D/D |
180 |
56,588 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-05-29 |
4 |
D |
$57.50 |
$218,040 |
D/D |
(3,792) |
59,334 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-05-22 |
4 |
AS |
$56.88 |
$56,876 |
I/I |
(1,000) |
46,195 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-05-21 |
4 |
AS |
$56.19 |
$86,817 |
I/I |
(1,545) |
47,195 |
|
- |
|
Lawlis V Bryan |
Director |
|
2014-05-16 |
4 |
AS |
$56.87 |
$96,672 |
D/D |
(1,700) |
9,700 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-05-16 |
4 |
S |
$56.86 |
$105,994 |
D/D |
(1,864) |
60,950 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-05-16 |
4 |
AS |
$56.91 |
$57,136 |
D/D |
(1,004) |
20,980 |
|
- |
|
Bienaime Jean Jacques |
Chief Executive Officer |
|
2014-05-15 |
4 |
D |
$57.44 |
$283,294 |
D/D |
(4,932) |
180,257 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-05-15 |
4 |
D |
$57.44 |
$116,948 |
D/D |
(2,036) |
62,814 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-05-15 |
4 |
D |
$57.44 |
$62,954 |
D/D |
(1,096) |
21,984 |
|
- |
|
Spiegelman Daniel K |
EVP, Chief Financial Officer |
|
2014-05-15 |
4 |
D |
$57.44 |
$71,283 |
D/D |
(1,241) |
63,126 |
|
- |
|
Mueller Brian |
VP, Corporate Controller |
|
2014-05-15 |
4 |
D |
$57.44 |
$11,890 |
D/D |
(207) |
8,290 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-05-13 |
4/A |
S |
$58.23 |
$83,498 |
D/D |
(1,434) |
63,415 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-05-13 |
4 |
S |
$58.23 |
$83,498 |
D/D |
(1,434) |
64,850 |
|
- |
|
Ajer Jeffrey Robert |
SVP, Chief Commercial Of |
|
2014-05-13 |
4 |
AS |
$58.18 |
$27,809 |
D/D |
(478) |
23,080 |
|
- |
|
Fuchs Henry J |
EVP, Chief Medical Officer |
|
2014-05-12 |
4/A |
D |
$59.30 |
$177,959 |
D/D |
(3,001) |
64,849 |
|
- |
|
Davis George Eric |
SVP, General Counsel |
|
2014-05-12 |
4 |
D |
$57.44 |
$62,954 |
D/D |
(1,096) |
56,768 |
|
- |
|
1276 Records found
|
|
Page 2 of 52 |
|
|